

Milan, 9 July 2021 – With reference to the article appeared today in an Italian newspaper, Recordati announces that it has started, in the best interest of the Company and all its stakeholders, a process aimed at further strengthening the governance of the business, so as to further support the continued development of the Group in the medium and long term. The outcome of such process will be communicated as soon as finalised.

***Recordati**, established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, proprietary and under license, in a number of therapeutic areas, including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties, with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

Recordati website: www.recordati.com

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39) 02 76004736, (39) 02 76004745

e-mail: norismorano@studionorismorano.com

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities, and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

VIA M. CIVITALI 1

20148 MILAN, ITALY

TEL. +(39) 024 87 871

FAX +(39) 024 007 3747

€ 26,140,644.50 SHARE CAPITAL, FULLY PAID IN

MILAN, MONZA, BRIANZA and LODI BUSINESS REGISTER 00748210150

TAX CODE/VAT NO. 00748210150

MILAN ECONOMIC AND ADMINISTRATIVE INDEX 401832

Company under the Management and Coordination of Rossini Luxembourg S.à.r.l